{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:53:53Z","timestamp":1769849633792,"version":"3.49.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s11096-022-01525-1","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T20:02:52Z","timestamp":1673640172000},"page":"461-472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The impact of high on-treatment platelet reactivity and fibrinogen levels on ischemic events in patients with ST elevation myocardial infarction: a prospective observational study"],"prefix":"10.1007","volume":"45","author":[{"given":"Yao","family":"Yao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoye","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shikun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6353-7767","authenticated-orcid":false,"given":"Qianzhou","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"1525_CR1","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1161\/cir.0000000000000404","volume":"134","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, et al. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet Therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines: an update of the 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention, 2011 ACCF\/AHA guideline for coronary artery bypass graft surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA\/ACC guideline for the management of patients with Non-ST-elevation acute coronary syndromes, and 2014 ACC\/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134:e123\u201355. https:\/\/doi.org\/10.1161\/cir.0000000000000404.","journal-title":"Circulation"},{"key":"1525_CR2","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","volume":"56","author":"L Bonello","year":"2010","unstructured":"Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919\u201333. https:\/\/doi.org\/10.1016\/j.jacc.2010.04.047.","journal-title":"J Am Coll Cardiol"},{"key":"1525_CR3","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","volume":"62","author":"US Tantry","year":"2013","unstructured":"Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62:2261\u201373. https:\/\/doi.org\/10.1016\/j.jacc.2013.07.101.","journal-title":"J Am Coll Cardiol"},{"key":"1525_CR4","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1161\/circulationaha.117.030190","volume":"137","author":"YD Tang","year":"2018","unstructured":"Tang YD, Wang W, Yang M, et al. Randomized comparisons of double-dose clopidogrel or adjunctive cilostazol versus standard dual antiplatelet in patients with high posttreatment platelet reactivity: results of the CREATIVE trial. Circulation. 2018;137:2231\u201345. https:\/\/doi.org\/10.1161\/circulationaha.117.030190.","journal-title":"Circulation"},{"key":"1525_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/09537100400020161","volume":"16","author":"HK Breddin","year":"2005","unstructured":"Breddin HK. Can platelet aggregometry be standardized? Platelets. 2005;16:151\u20138. https:\/\/doi.org\/10.1080\/09537100400020161.","journal-title":"Platelets"},{"key":"1525_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejcts.2008.02.024","volume":"34","author":"J Dunning","year":"2008","unstructured":"Dunning J, Versteegh M, Fabbri A, et al. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg. 2008;34:73\u201392. https:\/\/doi.org\/10.1016\/j.ejcts.2008.02.024.","journal-title":"Eur J Cardiothorac Surg"},{"key":"1525_CR7","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ahj.2010.05.034","volume":"160","author":"PA Gurbel","year":"2010","unstructured":"Gurbel PA, Bliden KP, Navickas IA, et al. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J. 2010;160:346\u201354. https:\/\/doi.org\/10.1016\/j.ahj.2010.05.034.","journal-title":"Am Heart J"},{"key":"1525_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.5482\/ha-1133","volume":"31","author":"AR Rechner","year":"2011","unstructured":"Rechner AR. Platelet function testing in clinical diagnostics. Hamostaseologie. 2011;31:79\u201387. https:\/\/doi.org\/10.5482\/ha-1133.","journal-title":"Hamostaseologie"},{"key":"1525_CR9","doi-asserted-by":"publisher","first-page":"e01","DOI":"10.15420\/cfr.2020.22","volume":"7","author":"AS Rali","year":"2020","unstructured":"Rali AS, Salem AM, Gebre M, et al. Viscoelastic haemostatic assays in cardiovascular critical care. Card Fail Rev. 2020;7:e01. https:\/\/doi.org\/10.15420\/cfr.2020.22.","journal-title":"Card Fail Rev"},{"key":"1525_CR10","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.jacc.2005.01.034","volume":"45","author":"TA Nguyen","year":"2005","unstructured":"Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005;45:1157\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2005.01.034.","journal-title":"J Am Coll Cardiol"},{"key":"1525_CR11","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045\u201357. https:\/\/doi.org\/10.1056\/NEJMoa0904327.","journal-title":"N Engl J Med"},{"key":"1525_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119\u201377. https:\/\/doi.org\/10.1093\/eurheartj\/ehx393.","journal-title":"Eur Heart J"},{"key":"1525_CR13","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2021","unstructured":"Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42:1289\u2013367. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa575.","journal-title":"Eur Heart J"},{"key":"1525_CR14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ahj.2010.11.025","volume":"162","author":"KP Bliden","year":"2011","unstructured":"Bliden KP, Tantry US, Storey RF, et al. The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET\/OFFSET and RESPOND studies. Am Heart J. 2011;162:160\u20135. https:\/\/doi.org\/10.1016\/j.ahj.2010.11.025.","journal-title":"Am Heart J"},{"key":"1525_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.vph.2015.04.014","volume":"77","author":"M Verdoia","year":"2016","unstructured":"Verdoia M, Sartori C, Pergolini P, et al. Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation. Vasc Pharmacol. 2016;77:48\u201353. https:\/\/doi.org\/10.1016\/j.vph.2015.04.014.","journal-title":"Vasc Pharmacol"},{"key":"1525_CR16","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/crd.0000000000000034","volume":"22","author":"I Cavallari","year":"2014","unstructured":"Cavallari I, Nusca A, Ricottini E, et al. Prognostic role of platelet reactivity in patients with acute coronary syndromes. Cardiol Rev. 2014;22:313\u20138. https:\/\/doi.org\/10.1097\/crd.0000000000000034.","journal-title":"Cardiol Rev"},{"key":"1525_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3109\/10408363.2014.913549","volume":"51","author":"M Krintus","year":"2014","unstructured":"Krintus M, Kozinski M, Kubica J, et al. Critical appraisal of inflammatory markers in cardiovascular risk stratification. Crit Rev Clin Lab Sci. 2014;51:263\u201379. https:\/\/doi.org\/10.3109\/10408363.2014.913549.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"1525_CR18","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.atherosclerosis.2010.06.026","volume":"212","author":"JC Kaski","year":"2010","unstructured":"Kaski JC, Fern\u00e1ndez-Berg\u00e9s DJ, Consuegra-S\u00e1nchez L, et al. A comparative study of biomarkers for risk prediction in acute coronary syndrome-results of the SIESTA (Systemic Inflammation Evaluation in non-ST-elevation Acute coronary syndrome) study. Atherosclerosis. 2010;212:636\u201343. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2010.06.026.","journal-title":"Atherosclerosis"},{"key":"1525_CR19","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/qjmed\/hcg129","volume":"96","author":"S Kamath","year":"2003","unstructured":"Kamath S, Lip GY. Fibrinogen: biochemistry, epidemiology and determinants. QJM. 2003;96:711\u201329. https:\/\/doi.org\/10.1093\/qjmed\/hcg129.","journal-title":"QJM"},{"key":"1525_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5551\/jat.2600","volume":"17","author":"E Corrado","year":"2010","unstructured":"Corrado E, Rizzo M, Coppola G, et al. An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb. 2010;17:1\u201311. https:\/\/doi.org\/10.5551\/jat.2600.","journal-title":"J Atheroscler Thromb"},{"key":"1525_CR21","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.jacc.2008.05.054","volume":"52","author":"L Ang","year":"2008","unstructured":"Ang L, Palakodeti V, Khalid A, et al. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol. 2008;52:1052\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2008.05.054.","journal-title":"J Am Coll Cardiol"},{"key":"1525_CR22","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1749-6632.2001.tb03521.x","volume":"936","author":"JS Bennett","year":"2001","unstructured":"Bennett JS. Platelet-fibrinogen interactions. Ann N Y Acad Sci. 2001;936:340\u201354. https:\/\/doi.org\/10.1111\/j.1749-6632.2001.tb03521.x.","journal-title":"Ann N Y Acad Sci"},{"key":"1525_CR23","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1016\/j.thromres.2010.01.003","volume":"125","author":"TF Althoff","year":"2010","unstructured":"Althoff TF, Fischer M, Langer E, et al. Sustained enhancement of residual platelet reactivity after coronary stenting in patients with myocardial infarction compared to elective patients. Thromb Res. 2010;125:e190\u20136. https:\/\/doi.org\/10.1016\/j.thromres.2010.01.003.","journal-title":"Thromb Res"},{"key":"1525_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jacc.2012.09.037","volume":"61","author":"L Ang","year":"2013","unstructured":"Ang L, Thani KB, Ilapakurti M, et al. Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention. J Am Coll Cardiol. 2013;61:23\u201334. https:\/\/doi.org\/10.1016\/j.jacc.2012.09.037.","journal-title":"J Am Coll Cardiol"},{"key":"1525_CR25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2307\/2531021","volume":"39","author":"DA Schoenfeld","year":"1983","unstructured":"Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics. 1983;39:499\u2013503.","journal-title":"Biometrics"},{"key":"1525_CR26","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.4244\/eijv8i10a176","volume":"8","author":"P Tobbia","year":"2013","unstructured":"Tobbia P, Brodie BR, Witzenbichler B, et al. Adverse event rates following primary PCI for STEMI at US and non-US hospitals: three-year analysis from the HORIZONS-AMI trial. EuroIntervention. 2013;8:1134\u201342. https:\/\/doi.org\/10.4244\/eijv8i10a176.","journal-title":"EuroIntervention"},{"key":"1525_CR27","doi-asserted-by":"publisher","first-page":"e5280","DOI":"10.7759\/cureus.5280","volume":"11","author":"I Poudel","year":"2019","unstructured":"Poudel I, Tejpal C, Rashid H, et al. Major adverse cardiovascular events: an inevitable outcome of ST-elevation myocardial infarction? A literature review. Cureus. 2019;11:e5280. https:\/\/doi.org\/10.7759\/cureus.5280.","journal-title":"Cureus"},{"key":"1525_CR28","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1253\/circj.CJ-21-0098","volume":"85","author":"M Sawano","year":"2021","unstructured":"Sawano M, Kohsaka S, Ishii H, et al. One-year outcome after percutaneous coronary intervention for acute coronary syndrome\u2014An analysis of 20,042 patients from a Japanese nationwide registry. Circ J. 2021;85:1756\u201367. https:\/\/doi.org\/10.1253\/circj.CJ-21-0098.","journal-title":"Circ J"},{"key":"1525_CR29","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1001\/jama.2011.1332","volume":"306","author":"G Parodi","year":"2011","unstructured":"Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA. 2011;306:1215\u201323. https:\/\/doi.org\/10.1001\/jama.2011.1332.","journal-title":"JAMA"},{"key":"1525_CR30","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.4244\/eij-d-16-00255","volume":"12","author":"G Parodi","year":"2017","unstructured":"Parodi G, Bellandi B, Tarantini G, et al. Clinical events beyond one year after an acute coronary syndrome: insights from the RECLOSE 2-ACS study. EuroIntervention. 2017;12:2018\u201324. https:\/\/doi.org\/10.4244\/eij-d-16-00255.","journal-title":"EuroIntervention"},{"key":"1525_CR31","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3109\/00365513.2014.993696","volume":"75","author":"N Tang","year":"2015","unstructured":"Tang N, Yin S, Sun Z, et al. The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients. Scand J Clin Lab Invest. 2015;75:223\u20139. https:\/\/doi.org\/10.3109\/00365513.2014.993696.","journal-title":"Scand J Clin Lab Invest"},{"key":"1525_CR32","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1007\/s12325-019-01032-2","volume":"36","author":"X Zhao","year":"2019","unstructured":"Zhao X, Wu H, Xu H, et al. Association between residual platelet reactivity on clopidogrel treatment and severity of coronary atherosclerosis: intrinsic hypercoagulability as a mediator. Adv Ther. 2019;36:2296\u2013309. https:\/\/doi.org\/10.1007\/s12325-019-01032-2.","journal-title":"Adv Ther"},{"key":"1525_CR33","doi-asserted-by":"publisher","first-page":"736466","DOI":"10.3389\/fcvm.2021.736466","volume":"8","author":"J Li","year":"2021","unstructured":"Li J, Yuan D, Jiang L, et al. Similar inflammatory biomarkers reflect different platelet reactivity in percutaneous coronary intervention patients treated with clopidogrel: a large-sample study from China. Front Cardiovasc Med. 2021;8:736466. https:\/\/doi.org\/10.3389\/fcvm.2021.736466.","journal-title":"Front Cardiovasc Med"},{"key":"1525_CR34","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1016\/j.jacc.2014.02.545","volume":"63","author":"F Alfonso","year":"2014","unstructured":"Alfonso F, Byrne RA, Rivero F, et al. Current treatment of in-stent restenosis. J Am Coll Cardiol. 2014;63:2659\u201373. https:\/\/doi.org\/10.1016\/j.jacc.2014.02.545.","journal-title":"J Am Coll Cardiol"},{"key":"1525_CR35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/heartjnl-2013-304933","volume":"100","author":"S Cassese","year":"2014","unstructured":"Cassese S, Byrne RA, Tada T, et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart. 2014;100:153\u20139. https:\/\/doi.org\/10.1136\/heartjnl-2013-304933.","journal-title":"Heart"},{"key":"1525_CR36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2174\/1573403x15666190620141129","volume":"16","author":"H Haybar","year":"2020","unstructured":"Haybar H, Pezeshki SMS, Saki N. Platelets in in-stent restenosis: from fundamental role to possible prognostic application. Curr Cardiol Rev. 2020;16:285\u201391. https:\/\/doi.org\/10.2174\/1573403x15666190620141129.","journal-title":"Curr Cardiol Rev"},{"key":"1525_CR37","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.cjca.2018.08.024","volume":"34","author":"Z Jiang","year":"2018","unstructured":"Jiang Z, Zhang R, Sun M, et al. Effect of clopidogrel vs ticagrelor on platelet aggregation and inflammation markers after percutaneous coronary intervention for ST-elevation myocardial infarction. Can J Cardiol. 2018;34:1606\u201312. https:\/\/doi.org\/10.1016\/j.cjca.2018.08.024.","journal-title":"Can J Cardiol"},{"key":"1525_CR38","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1517\/14656566.2015.1074180","volume":"16","author":"PO Guimar\u00e3es","year":"2015","unstructured":"Guimar\u00e3es PO, Tricoci P. Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose? Expert Opin Pharmacother. 2015;16:1983\u201395. https:\/\/doi.org\/10.1517\/14656566.2015.1074180.","journal-title":"Expert Opin Pharmacother"},{"key":"1525_CR39","doi-asserted-by":"publisher","first-page":"540","DOI":"10.47391\/jpma.029","volume":"71","author":"Z Dong","year":"2021","unstructured":"Dong Z, Zhai H, Pan L, et al. Stronger inhibitory effects of Ticagrelor plus aspirin compared with Clopidogrel plus aspirin on arachidonic acid-induced platelet aggregation in patients with acute coronary syndrome with PCI. J Pak Med Assoc. 2021;71:540\u20132. https:\/\/doi.org\/10.47391\/jpma.029.","journal-title":"J Pak Med Assoc"},{"key":"1525_CR40","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1038\/s41598-019-40628-0","volume":"9","author":"P Adamski","year":"2019","unstructured":"Adamski P, Buszko K, Sikora J, et al. Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor. Sci Rep. 2019;9:3924. https:\/\/doi.org\/10.1038\/s41598-019-40628-0.","journal-title":"Sci Rep"},{"key":"1525_CR41","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1161\/cir.0000000000000757","volume":"141","author":"SS Virani","year":"2020","unstructured":"Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141:e139\u2013596. https:\/\/doi.org\/10.1161\/cir.0000000000000757.","journal-title":"Circulation"},{"key":"1525_CR42","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1160\/th16-10-0496","volume":"117","author":"RP Kreutz","year":"2017","unstructured":"Kreutz RP, Schmeisser G, Maatman B, et al. Fibrin clot strength measured by thrombelastography and outcomes after percutaneous coronary intervention. Thromb Haemost. 2017;117:426\u20138. https:\/\/doi.org\/10.1160\/th16-10-0496.","journal-title":"Thromb Haemost"},{"key":"1525_CR43","doi-asserted-by":"publisher","first-page":"3767128","DOI":"10.1155\/2019\/3767128","volume":"2019","author":"G Biolik","year":"2019","unstructured":"Biolik G, Gajniak D, Kubicz M, et al. The influence of inflammation on fibrinogen turnover and redistribution of the hemostatic balance to a prothrombotic state in high on-treatment platelet reactivity-dual poor responder (HTPR-DPR) patients. Mediat Inflamm. 2019;2019:3767128. https:\/\/doi.org\/10.1155\/2019\/3767128.","journal-title":"Mediat Inflamm"},{"key":"1525_CR44","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1182\/blood-2018-07-818211","volume":"133","author":"JP Luyendyk","year":"2019","unstructured":"Luyendyk JP, Schoenecker JG, Flick MJ. The multifaceted role of fibrinogen in tissue injury and inflammation. Blood. 2019;133:511\u201320. https:\/\/doi.org\/10.1182\/blood-2018-07-818211.","journal-title":"Blood"},{"key":"1525_CR45","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1001\/jama.1987.03400090067035","volume":"258","author":"WB Kannel","year":"1987","unstructured":"Kannel WB, Wolf PA, Castelli WP, et al. Fibrinogen and risk of cardiovascular disease. The Framingham study. JAMA. 1987;258:1183\u20136.","journal-title":"JAMA"},{"key":"1525_CR46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.coph.2004.10.003","volume":"5","author":"M Nieuwdorp","year":"2005","unstructured":"Nieuwdorp M, Stroes ES, Meijers JC, et al. Hypercoagulability in the metabolic syndrome. Curr Opin Pharmacol. 2005;5:155\u20139. https:\/\/doi.org\/10.1016\/j.coph.2004.10.003.","journal-title":"Curr Opin Pharmacol"},{"key":"1525_CR47","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3390\/ijms23010193","volume":"23","author":"S Surma","year":"2021","unstructured":"Surma S, Banach M. Fibrinogen and atherosclerotic cardiovascular diseases-review of the literature and clinical studies. Int J Mol Sci. 2021;23:193. https:\/\/doi.org\/10.3390\/ijms23010193.","journal-title":"Int J Mol Sci"},{"key":"1525_CR48","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1182\/blood-2008-03-145821","volume":"114","author":"H Yang","year":"2009","unstructured":"Yang H, Lang S, Zhai Z, et al. Fibrinogen is required for maintenance of platelet intracellular and cell-surface P-selectin expression. Blood. 2009;114:425\u201336. https:\/\/doi.org\/10.1182\/blood-2008-03-145821.","journal-title":"Blood"},{"key":"1525_CR49","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.atherosclerosis.2007.03.020","volume":"197","author":"M Jaster","year":"2008","unstructured":"Jaster M, Horstkotte D, Willich T, et al. The amount of fibrinogen-positive platelets predicts the occurrence of in-stent restenosis. Atherosclerosis. 2008;197:190\u20136. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2007.03.020.","journal-title":"Atherosclerosis"},{"key":"1525_CR50","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1177\/1076029616629210","volume":"23","author":"MM Tabakc\u0131","year":"2017","unstructured":"Tabakc\u0131 MM, Gerin F, Sunbul M, et al. Relation of plasma fibrinogen level with the presence, severity, and complexity of coronary artery disease. Clin Appl Thromb Hemost. 2017;23:638\u201344. https:\/\/doi.org\/10.1177\/1076029616629210.","journal-title":"Clin Appl Thromb Hemost"},{"key":"1525_CR51","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.amjcard.2013.11.025","volume":"113","author":"JS Woo","year":"2014","unstructured":"Woo JS, Kim W, Jang HH, et al. Effect of platelet reactivity, endothelial function, and inflammatory status on outcomes in patients with stable angina pectoris on clopidogrel therapy. Am J Cardiol. 2014;113:786\u201392. https:\/\/doi.org\/10.1016\/j.amjcard.2013.11.025.","journal-title":"Am J Cardiol"},{"key":"1525_CR52","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1016\/j.jacc.2010.12.047","volume":"57","author":"G Campo","year":"2011","unstructured":"Campo G, Parrinello G, Ferraresi P, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol. 2011;57:2474\u201383. https:\/\/doi.org\/10.1016\/j.jacc.2010.12.047.","journal-title":"J Am Coll Cardiol"},{"key":"1525_CR53","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1055\/s-0035-1570081","volume":"42","author":"M Chatterjee","year":"2016","unstructured":"Chatterjee M, Geisler T. Inflammatory contribution of platelets revisited: new players in the arena of inflammation. Semin Thromb Hemost. 2016;42:205\u201314. https:\/\/doi.org\/10.1055\/s-0035-1570081.","journal-title":"Semin Thromb Hemost"},{"key":"1525_CR54","doi-asserted-by":"publisher","first-page":"e003370","DOI":"10.1161\/jaha.116.003370","volume":"5","author":"T Gupta","year":"2016","unstructured":"Gupta T, Kolte D, Khera S, et al. Smoker\u2019s paradox in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. J Am Heart Assoc. 2016;5:e003370. https:\/\/doi.org\/10.1161\/jaha.116.003370.","journal-title":"J Am Heart Assoc"},{"key":"1525_CR55","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jacc.2013.03.037","volume":"62","author":"PA Gurbel","year":"2013","unstructured":"Gurbel PA, Bliden KP, Logan DK, et al. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J Am Coll Cardiol. 2013;62:505\u201312. https:\/\/doi.org\/10.1016\/j.jacc.2013.03.037.","journal-title":"J Am Coll Cardiol"},{"key":"1525_CR56","doi-asserted-by":"publisher","first-page":"e007982","DOI":"10.1161\/circinterventions.119.007982","volume":"12","author":"R Gupta","year":"2019","unstructured":"Gupta R, Kirtane AJ, Liu Y, et al. Impact of smoking on platelet reactivity and clinical outcomes after percutaneous coronary intervention: findings from the ADAPT-DES study. Circ Cardiovasc Interv. 2019;12:e007982. https:\/\/doi.org\/10.1161\/circinterventions.119.007982.","journal-title":"Circ Cardiovasc Interv"},{"key":"1525_CR57","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jacc.2008.04.045","volume":"52","author":"KP Bliden","year":"2008","unstructured":"Bliden KP, Dichiara J, Lawal L, et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol. 2008;52:531\u20133. https:\/\/doi.org\/10.1016\/j.jacc.2008.04.045.","journal-title":"J Am Coll Cardiol"},{"key":"1525_CR58","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.thromres.2013.05.006","volume":"132","author":"L Zhang","year":"2013","unstructured":"Zhang L, Chen Y, Jin Y, et al. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients. Thromb Res. 2013;132:81\u20137. https:\/\/doi.org\/10.1016\/j.thromres.2013.05.006.","journal-title":"Thromb Res"},{"key":"1525_CR59","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.vph.2015.10.005","volume":"77","author":"R Marcucci","year":"2016","unstructured":"Marcucci R, Grifoni E, Giusti B. On-treatment platelet reactivity: state of the art and perspectives. Vascul Pharmacol. 2016;77:8\u201318. https:\/\/doi.org\/10.1016\/j.vph.2015.10.005.","journal-title":"Vascul Pharmacol"},{"key":"1525_CR60","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3109\/09537104.2012.658106","volume":"23","author":"R Marcucci","year":"2012","unstructured":"Marcucci R, Giusti B, Paniccia R, et al. High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers. Platelets. 2012;23:586\u201393. https:\/\/doi.org\/10.3109\/09537104.2012.658106.","journal-title":"Platelets"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-022-01525-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-022-01525-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-022-01525-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T10:36:27Z","timestamp":1682678187000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-022-01525-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1525"],"URL":"https:\/\/doi.org\/10.1007\/s11096-022-01525-1","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]},"assertion":[{"value":"16 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author reports no conflicts of interest in this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}